Literature DB >> 6093976

Lytic, nontransforming Epstein-Barr virus (EBV) from a patient with chronic active EBV infection.

C Alfieri, F Ghibu, J H Joncas.   

Abstract

A new wild-type isolate of Epstein-Barr virus (EBV) was identified in follow-up studies of a case of chronic active EBV infection in an 8-year-old girl who had high titres of antibody to viral capsid antigen and early antigen (EA) (greater than 20 480 and 2560 respectively), persistent splenomegaly and abnormal immunologic features. More than 10 throat washings from this patient failed to transform cord blood lymphocytes (CBL), but at least 7 were able to induce EA in Raji cells. Supernatants from cultures of the lymphoblastoid cell line obtained by in-vitro infection of this patient's leukocytes with the B95-8 strain of EBV revealed a herpesvirus particle when examined by electron microscopy. The same supernatants were unable to transform CBL but could induce EA in Raji cells upon superinfection. In 30 or more trials the patient's lymphocytes never transformed spontaneously but did become positive for EBV nuclear antigen and EA in the first week of culture at least twice. Parallel studies performed on the father of the patient yielded similar results. This, then, is the first report documenting lytic activity associated with a wild-type EBV isolate.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6093976      PMCID: PMC1483675     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  9 in total

1.  Biological differences between Epstein-Barr virus (EBV) strains with regard to lymphocyte transforming ability, superinfection and antigen induction.

Authors:  J Menezes; W Leibold; G Klein
Journal:  Exp Cell Res       Date:  1975-05       Impact factor: 3.905

2.  Immunofluorescence in cells derived from Burkitt's lymphoma.

Authors:  G Henle; W Henle
Journal:  J Bacteriol       Date:  1966-03       Impact factor: 3.490

3.  Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines.

Authors:  B M Reedman; G Klein
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

4.  A simple technique for demonstrating centromeric heterochromatin.

Authors:  A T Sumner
Journal:  Exp Cell Res       Date:  1972-11       Impact factor: 3.905

5.  Identification of human chromosomes by DNA-binding fluorescent agents.

Authors:  T Caspersson; L Zech; C Johansson; E J Modest
Journal:  Chromosoma       Date:  1970       Impact factor: 4.316

Review 6.  The biology and chemistry of Epstein-Barr virus.

Authors:  E Kieff; T Dambaugh; M Heller; W King; A Cheung; V van Santen; M Hummel; C Beisel; S Fennewald; K Hennessy; T Heineman
Journal:  J Infect Dis       Date:  1982-10       Impact factor: 5.226

7.  Epstein-Barr virus-induced diseases in boys with the X-linked lymphoproliferative syndrome (XLP): update on studies of the registry.

Authors:  D T Purtilo; K Sakamoto; V Barnabei; J Seeley; T Bechtold; G Rogers; J Yetz; S Harada
Journal:  Am J Med       Date:  1982-07       Impact factor: 4.965

8.  Herpes-type virus and chromosome marker in normal leukocytes after growth with irradiated Burkitt cells.

Authors:  W Henle; V Diehl; G Kohn; H Zur Hausen; G Henle
Journal:  Science       Date:  1967-09-01       Impact factor: 47.728

9.  A familial syndrome of susceptibility to chronic active Epstein-Barr virus infection.

Authors:  J H Joncas; F Ghibu; M Blagdon; S Montplaisir; I Stefanescu; J Menezes
Journal:  Can Med Assoc J       Date:  1984-02-01       Impact factor: 8.262

  9 in total
  8 in total

1.  Risk factors in pediatric AIDS.

Authors:  J H Joncas; N Lapointe; M V O'Shaughnessy
Journal:  Can Med Assoc J       Date:  1985-03-15       Impact factor: 8.262

Review 2.  Progress and problems in understanding and managing primary Epstein-Barr virus infections.

Authors:  Oludare A Odumade; Kristin A Hogquist; Henry H Balfour
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

3.  Biomolecular analysis of a defective nontransforming Epstein-Barr virus (EBV) from a patient with chronic active EBV infection.

Authors:  C Alfieri; J H Joncas
Journal:  J Virol       Date:  1987-10       Impact factor: 5.103

4.  The immune response to human metapneumovirus is associated with aberrant immunity and impaired virus clearance in BALB/c mice.

Authors:  Rene Alvarez; Ralph A Tripp
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

Review 5.  Severe chronic active Epstein-Barr virus infection syndrome.

Authors:  M Okano; S Matsumoto; T Osato; Y Sakiyama; G M Thiele; D T Purtilo
Journal:  Clin Microbiol Rev       Date:  1991-01       Impact factor: 26.132

6.  Optimal treatment for chronic active Epstein-Barr virus disease.

Authors:  Jeffrey I Cohen
Journal:  Pediatr Transplant       Date:  2009-06

Review 7.  Chronic Active Epstein-Barr Virus Disease.

Authors:  Hiroshi Kimura; Jeffrey I Cohen
Journal:  Front Immunol       Date:  2017-12-22       Impact factor: 7.561

8.  Construction and Characterization of a Humanized Anti-Epstein-Barr Virus gp350 Antibody with Neutralizing Activity in Cell Culture.

Authors:  Jerome E Tanner; Jing Hu; Caroline Alfieri
Journal:  Cancers (Basel)       Date:  2018-04-09       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.